FDA U.S. FOOD & DRUG ADMINISTRATION

June 2, 2025

The Honorable Josh Hawley
United States Senate
Washington, D.C. 20510

Dear Senator Hawley:

Thank you for your letter to the Food and Drug Administration (FDA or the Agency) regarding the safety of mifepristone for the medical termination of early pregnancy. I appreciate your continued interest in this topic.

FDA is committed to safeguarding public health by ensuring the safety, efficacy, and quality of the products it regulates. The Agency carefully evaluates the scientific data, leveraging rigorous science to make informed decisions. As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy. As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the Agency who review this data.

Mifepristone for medical termination of early pregnancy is the subject of pending litigation. FDA generally does not comment on matters that are the subject of pending litigation and therefore is unable to provide further information on this topic at this time.

Thank you again for contacting the Agency regarding this matter. Please do not hesitate to reach out if there are any additional questions.

Sincerely,

Martin A. Makary, M.D., M.P.H.
Commissioner of Food and Drugs

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov